BR112018008746A8 - composições e métodos para a inibição de atividade de arginase - Google Patents

composições e métodos para a inibição de atividade de arginase

Info

Publication number
BR112018008746A8
BR112018008746A8 BR112018008746A BR112018008746A BR112018008746A8 BR 112018008746 A8 BR112018008746 A8 BR 112018008746A8 BR 112018008746 A BR112018008746 A BR 112018008746A BR 112018008746 A BR112018008746 A BR 112018008746A BR 112018008746 A8 BR112018008746 A8 BR 112018008746A8
Authority
BR
Brazil
Prior art keywords
methods
compositions
arginase activity
inhibiting arginase
compounds
Prior art date
Application number
BR112018008746A
Other languages
English (en)
Other versions
BR112018008746A2 (pt
BR112018008746B1 (pt
Inventor
Whitehouse Darren
B Sjogren Eric
Li Jim
Van Zandt Michael
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Priority to BR122020022275-1A priority Critical patent/BR122020022275B1/pt
Priority to BR122020022280-8A priority patent/BR122020022280B1/pt
Publication of BR112018008746A2 publication Critical patent/BR112018008746A2/pt
Publication of BR112018008746A8 publication Critical patent/BR112018008746A8/pt
Publication of BR112018008746B1 publication Critical patent/BR112018008746B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a invenção está relacionada a uma nova classe de compostos que exibem atividade inibidora em direção à arginase, e composições farmacêuticas que compreendem os compostos da invenção. também são fornecidos nesse relatório descritivo métodos de tratamento de câncer com os inibidores de arginase da invenção.
BR112018008746-7A 2015-10-30 2016-10-28 Composto, composição farmacêutica e uso do referido composto para fabricação de uma composição farmacêutica para o tratamento de cancêr BR112018008746B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122020022275-1A BR122020022275B1 (pt) 2015-10-30 2016-10-28 Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr
BR122020022280-8A BR122020022280B1 (pt) 2015-10-30 2016-10-28 Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562248632P 2015-10-30 2015-10-30
US62/248,632 2015-10-30
US201662281964P 2016-01-22 2016-01-22
US62/281,964 2016-01-22
US201662323034P 2016-04-15 2016-04-15
US62/323,034 2016-04-15
PCT/US2016/059342 WO2017075363A1 (en) 2015-10-30 2016-10-28 Compositions and methods for inhibiting arginase activity

Publications (3)

Publication Number Publication Date
BR112018008746A2 BR112018008746A2 (pt) 2018-10-30
BR112018008746A8 true BR112018008746A8 (pt) 2019-02-26
BR112018008746B1 BR112018008746B1 (pt) 2021-11-16

Family

ID=58631120

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122020022280-8A BR122020022280B1 (pt) 2015-10-30 2016-10-28 Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr
BR112018008746-7A BR112018008746B1 (pt) 2015-10-30 2016-10-28 Composto, composição farmacêutica e uso do referido composto para fabricação de uma composição farmacêutica para o tratamento de cancêr
BR122020022275-1A BR122020022275B1 (pt) 2015-10-30 2016-10-28 Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020022280-8A BR122020022280B1 (pt) 2015-10-30 2016-10-28 Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020022275-1A BR122020022275B1 (pt) 2015-10-30 2016-10-28 Composto inibidor de arginase, composição farmacêutica e uso do referido composto na fabricação de uma composição farmacêutica para o tratamento de cancêr

Country Status (36)

Country Link
US (4) US10065974B2 (pt)
EP (3) EP4011887B1 (pt)
JP (3) JP6833844B2 (pt)
KR (2) KR20220118559A (pt)
CN (4) CN113150015A (pt)
AU (3) AU2016343656B2 (pt)
BR (3) BR122020022280B1 (pt)
CA (1) CA3003271A1 (pt)
CL (4) CL2018001134A1 (pt)
CO (1) CO2018004750A2 (pt)
CR (3) CR20210389A (pt)
CY (1) CY1123557T1 (pt)
DK (1) DK3368541T3 (pt)
EA (1) EA038276B1 (pt)
EC (1) ECSP18040250A (pt)
ES (2) ES2808988T3 (pt)
HK (1) HK1252560A1 (pt)
HR (1) HRP20201046T1 (pt)
HU (1) HUE054972T2 (pt)
IL (3) IL258731B (pt)
LT (1) LT3368541T (pt)
MA (2) MA50636A (pt)
MD (1) MD3368541T2 (pt)
MX (1) MX2018005294A (pt)
MY (1) MY201783A (pt)
NZ (1) NZ742742A (pt)
PH (1) PH12018500899A1 (pt)
PL (1) PL3368541T3 (pt)
PT (1) PT3368541T (pt)
RS (1) RS60695B1 (pt)
SG (4) SG11201802961PA (pt)
SI (1) SI3368541T1 (pt)
TW (3) TWI734630B (pt)
UA (1) UA125289C2 (pt)
WO (1) WO2017075363A1 (pt)
ZA (4) ZA201803556B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
SI3559009T1 (sl) * 2016-12-22 2021-08-31 Calithera Biosciences, Inc. Sestavki in postopki za zaviranje arginazne dejavnosti
PE20200339A1 (es) 2017-05-12 2020-02-14 Calithera Biosciences Inc Metodo para preparar (3r, 4s)-3-acetamido-4-alil-n-(terc-butil)pirrolidina-3-carboxamida
CN111491937A (zh) * 2017-12-22 2020-08-04 广东新契生物医药科技有限公司 作为精氨酸酶抑制剂的杂环化合物
CN117180290A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
IL276813B2 (en) 2018-03-05 2024-09-01 Arcus Biosciences Inc History of 4-substituted 5-amino-octahydrocyclopenta[c]pyrrole-5-carboxylic acid, their pharmaceutical combinations and their use for the treatment of diseases
US20210040127A1 (en) * 2018-03-13 2021-02-11 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TWI723366B (zh) 2018-03-29 2021-04-01 波蘭商昂科艾倫迪治療法股份公司 二肽哌啶衍生物
EP3810615A4 (en) 2018-06-20 2022-03-30 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
WO2020160707A1 (en) * 2019-02-06 2020-08-13 Guangdong Newopp Biopharmaceuticals Co., Ltd. Alkylboronic acids as arginase inhibitors
EP3962897A4 (en) * 2019-05-02 2022-12-14 Aclaris Therapeutics, Inc. SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
CN110759843A (zh) * 2019-09-30 2020-02-07 东北师范大学 一种氟叠氮取代的四元杂环化合物的制备和应用
CN110734456A (zh) * 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme LLC ARGINASE INHIBITORS AND METHODS OF USE
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022016195A1 (en) 2020-07-17 2022-01-20 Incyte Corporation Processes for the preparation of arginase inhibitors and their synthetic intermediates
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US20240190876A1 (en) 2022-10-21 2024-06-13 Incyte Corporation Tricyclic Urea Compounds As JAK2 V617F Inhibitors
US20240317744A1 (en) 2023-03-13 2024-09-26 Incyte Corporation Bicyclic Ureas As Kinase Inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
CA2296080C (en) 1997-07-29 2005-02-01 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
WO1999019295A1 (en) 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US20040063666A1 (en) 1998-10-09 2004-04-01 David Christianson Compositions for inhibiting arginase activity
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
EP1299398A1 (en) 2000-07-06 2003-04-09 Fal Diagnostics Methods and kits for the detection of arginine compounds
CA2431080A1 (en) 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2007005620A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Arginase ii: a target treatment of aging heart and heart failure
CN101755130B (zh) 2007-07-12 2012-10-17 山洋电气株式会社 双重反转式轴流鼓风机
KR20150115959A (ko) * 2007-10-12 2015-10-14 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
RS58965B1 (sr) * 2009-01-26 2019-08-30 Univ Pennsylvania Inhibitori arginaze i postupci upotrebe
MX348422B (es) 2010-04-22 2017-06-12 Mars Inc Inhibidores de arginasa y sus aplicaciones terapeuticas.
SI2632927T1 (sl) * 2010-10-26 2016-08-31 Mars, Incorporated Boronati kot inhibitorji arginaze
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
JP5993459B2 (ja) 2011-10-19 2016-09-14 マーズ インコーポレイテッド アルギナーゼ阻害剤およびそれらの治療用途
AU2012325909B2 (en) 2011-10-20 2016-06-09 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
IN2014DN09678A (pt) 2012-04-18 2015-07-31 Mars Inc
US9717731B2 (en) * 2012-11-02 2017-08-01 Pharmacyclics Llc TEC family kinase inhibitor adjuvant therapy
EP3060251A4 (en) * 2013-10-25 2017-12-06 Pharmacyclics LLC Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
CN105879030A (zh) * 2014-09-30 2016-08-24 复旦大学 治疗肿瘤的增效药物复合物及其制备方法
KR20170129896A (ko) * 2015-03-20 2017-11-27 새미 오유 오피요 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도
EP3313410A4 (en) * 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
LT3368541T (lt) 2015-10-30 2020-09-25 Calithera Biosciences, Inc. Kompozicijos ir būdai, skirti arginazės aktyvumo inhibavimui
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne

Also Published As

Publication number Publication date
IL258731B (en) 2021-04-29
JP2021075543A (ja) 2021-05-20
BR122020022275B1 (pt) 2022-05-03
US20170121352A1 (en) 2017-05-04
CN108271371A (zh) 2018-07-10
ECSP18040250A (es) 2018-10-31
PT3368541T (pt) 2020-07-06
CL2019000821A1 (es) 2019-08-09
SG10201911402YA (en) 2020-02-27
HK1252560A1 (zh) 2019-05-31
AU2020286278B2 (en) 2022-03-17
HUE054972T2 (hu) 2021-10-28
CN113150016A (zh) 2021-07-23
SG10201911406TA (en) 2020-01-30
IL258731A (en) 2018-06-28
ZA201907093B (en) 2021-03-31
EP4011887A1 (en) 2022-06-15
AU2020286278A1 (en) 2021-01-14
PL3368541T3 (pl) 2020-11-02
TW201726692A (zh) 2017-08-01
BR112018008746A2 (pt) 2018-10-30
TWI710565B (zh) 2020-11-21
SG11201802961PA (en) 2018-05-30
BR112018008746B1 (pt) 2021-11-16
IL281503A (en) 2021-04-29
RS60695B1 (sr) 2020-09-30
WO2017075363A1 (en) 2017-05-04
CR20210390A (es) 2021-10-19
MA50636A (fr) 2021-04-14
ES2808988T3 (es) 2021-03-02
TWI734630B (zh) 2021-07-21
EA201891057A1 (ru) 2018-12-28
TW202110858A (zh) 2021-03-16
SI3368541T1 (sl) 2020-10-30
CL2018001134A1 (es) 2018-10-26
US10065974B2 (en) 2018-09-04
MX2018005294A (es) 2018-09-21
EP3693375B1 (en) 2022-02-16
NZ742742A (en) 2023-04-28
SG10202003966RA (en) 2020-06-29
CN113201002A (zh) 2021-08-03
CN108271371B (zh) 2021-02-09
AU2016343656B2 (en) 2020-09-17
DK3368541T3 (da) 2020-06-29
BR122020022280B1 (pt) 2022-05-03
HRP20201046T1 (hr) 2020-10-16
IL288225A (en) 2022-01-01
EP3368541A1 (en) 2018-09-05
JP6833844B2 (ja) 2021-02-24
US10844080B2 (en) 2020-11-24
UA125289C2 (uk) 2022-02-16
TW202146028A (zh) 2021-12-16
CO2018004750A2 (es) 2018-10-31
ES2910928T3 (es) 2022-05-17
CL2019000819A1 (es) 2019-08-09
EP3368541A4 (en) 2019-07-17
CN113150015A (zh) 2021-07-23
KR102434308B1 (ko) 2022-08-19
AU2016343656A1 (en) 2018-06-07
TWI775556B (zh) 2022-08-21
ZA201907091B (en) 2021-05-26
JP2022071010A (ja) 2022-05-13
US10851118B2 (en) 2020-12-01
CA3003271A1 (en) 2017-05-04
ZA201907092B (en) 2021-04-28
KR20220118559A (ko) 2022-08-25
US20210061822A1 (en) 2021-03-04
US20200223872A1 (en) 2020-07-16
MD3368541T2 (ro) 2020-09-30
CL2019000820A1 (es) 2019-08-09
EP4011887B1 (en) 2024-07-31
JP7032583B2 (ja) 2022-03-08
EP3368541B1 (en) 2020-05-27
PH12018500899A1 (en) 2018-10-29
CR20210389A (es) 2021-09-16
US20180346489A1 (en) 2018-12-06
JP2018533582A (ja) 2018-11-15
KR20180084063A (ko) 2018-07-24
AU2022203703A1 (en) 2022-06-16
LT3368541T (lt) 2020-09-25
IL281503B (en) 2022-01-01
CY1123557T1 (el) 2022-03-24
EA038276B1 (ru) 2021-08-04
MY201783A (en) 2024-03-18
CR20180282A (es) 2018-11-30
MA43131B1 (fr) 2020-07-29
ZA201803556B (en) 2021-02-24
EP3693375A1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
BR112018008746A8 (pt) composições e métodos para a inibição de atividade de arginase
MX2020013649A (es) Composiciones y metodos para inhibir la actividad de la arginasa.
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112018008877A8 (pt) inibidores de ret
BR112018004620A2 (pt) moduladores da expressão de kras
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112017019453A2 (pt) compostos e composições de alfa-cinamida como inibidores de hdac8
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112017000816A2 (pt) compostos inibitórios terapêuticos
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
BR112017023225A2 (pt) inibidor de proteína cinase
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
BR112017018198A2 (pt) inibição da atividade de olig2
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112018008506B8 (pt) Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
BR112017022340A2 (pt) 2-tiopirimidinonas
EA202191495A1 (ru) Композиции и способы ингибирования активности аргиназы
EA202191138A1 (ru) Композиции и способы для ингибирования активности аргиназы
BR112017021114A8 (pt) Compostos heterocíclicos como inibidores de lsd1
DOP2017000036A (es) Compuestos de azetidiniloxifenilpirrolidina

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/10/2016, OBSERVADAS AS CONDICOES LEGAIS.